Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080280 | 0.80 | MRGPRX4 (0.57) | MAPTL3MBTL1LMNAATMMRGPRX4 | |
| SCHEMBL29486044 | 0.78 | CYP1A2 (0.47) | MAPTLMNAMRGPRX4ALDH1A1RAB9A | |
| SCHEMBL22748806 | 0.78 | CYP1A2 (0.47) | MAPTLMNAMRGPRX4ALDH1A1RAB9A | |
| SCHEMBL22748948 | 0.78 | MASP2 (0.51) | PLK1MAPTLMNAATMALDH1A1 | |
| SCHEMBL29485930 | 0.78 | MASP2 (0.51) | PLK1MAPTLMNAATMALDH1A1 | |
| SCHEMBL22748931 | 0.77 | MAPT (0.48) | PLK1MAPTMRGPRX4ALDH1A1RAB9A | |
| SCHEMBL30029803 | 0.77 | MAPT (0.48) | PLK1MAPTMRGPRX4ALDH1A1RAB9A | |
| SCHEMBL4810956 | 0.77 | ALDH1A1 (0.57) | MAPTLMNAALDH1A1RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL7476448 | 0.76 | IDO1 (0.56) | MAPTLMNAALDH1A1RAB9ANPC1 | |
| SCHEMBL11412124 | 0.75 | MAPT (0.44) | PLK1MAPTL3MBTL1LMNAMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403144-B2 | HECT E3 ligase inhibitors and uses thereof | IFOM —FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2025-09-02 | — | — | US | disclosed |
| EP-3976185-B1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM ST FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS (IT) | 2024-02-14 | — | — | EP | disclosed |
| US-20220339163-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2022-10-27 | — | — | US | disclosed |
| EP-3976185-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM - Fondazione Istituto FIRC di Oncologia Molecolare (IT) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020245213-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339163-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | NEDD4, ITCH, UBE3A | PLK1 341/4885MAPT 365/4885L3MBTL1 1165/4885 |
| US-12403144-B2 | HECT E3 ligase inhibitors and uses thereof | NEDD4, ITCH, UBE3A | PLK1 341/4885MAPT 365/4885L3MBTL1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.